1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2. Bhargava R, Striebel J, Beriwal S, Flickinger J, Oniski A, Ahrendt G et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009; 2: 444-455.
3. Cárdenas-Sánchez J, Erazo A, Arce-Salinas C, Bargalló-Rocha JE, Bautista-Piña V, Cervantes-Sánchez G et al. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019. Gac Mex Oncol. 2019; 18: 141-231.
4. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG et al. US Incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106 (5): dju055.
5. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Sys Rev. 2003; 2: CD002747.